Previous 10 | Next 10 |
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May 15 th . Novan management will host a conference call and live audio web...
Published results from a National Psoriasis Foundation-fielded survey included responses from more than 400 patients across US 1 Findings highlight impact on patient adherence of early onset of improvement with topical psoriasis medications 1 WYNZORA® (calci...
DURHAM, N.C., April 20, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host an Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD...
2023-03-30 13:30:24 ET Novan ( NASDAQ: NOVN ) is trading 12.1% higher after the company posted better-than-expected full-year result helped by strong sales of medical dermatology products. License and collaboration revenues were $7.8M vs $2.8M, a year ago. Researc...
2023-03-30 12:42:05 ET Novan Inc. (NOVN) Q4 2022 Earnings Conference Call March 30, 2023 8:30 am ET Company Participants Paula Brown Stafford - President, Chief Executive Officer John Donofrio - Executive Vice President, Chief Operating Officer John Gay - Chief F...
2023-03-30 06:33:00 ET Novan press release ( NASDAQ: NOVN ): FY GAAP EPS of -$1.42 beats by $0.10 . Revenue of $23.7M (+690.0% Y/Y) beats by $4.34M . As of December 31, 2022, Novan had a total cash and cash equivalents balance of $12.3 million. For furthe...
– Berdazimer gel, 10.3% (SB206) assigned PDUFA goal date of January 5, 2024 – – Strong year-over-year prescription growth across three promoted products, RHOFADE, WYNZORA and MINOLIRA – – Company to host conference call today at 8:30 a.m. E...
2023-03-25 10:30:03 ET Summary Ligand’s strategy of providing development capital to high-quality assets with capable teams is paying off, as evidenced by the recent positive developments and advancements in its product pipeline. Ligand Pharmaceuticals has recently announce...
DURHAM, N.C., March 23, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its full year 2022 financial results on Thursday, March 30 th . Novan management will host a conference call and live audio w...
Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusion All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including ind...
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...